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AbstrACt
Introduction Adverse pregnancy outcomes, such as 
hypertensive disorders of pregnancy (HDP), gestational 
diabetes (GDM) and preterm birth have been linked to 
maternal cardiovascular disease in later life. Pre-eclampsia 
(PE) is associated with an increased risk of postpartum 
microalbuminuria, but there is no clear consensus on 
whether HDP increases the risk of maternal chronic kidney 
disease (CKD) and end-stage kidney disease (ESKD). 
Similarly, it is uncertain whether GDM, preterm birth and 
delivery of low birth-weight infants independently predict 
the risk of maternal renal disease in later life. The aims 
of this proposed systematic review and meta-analysis 
are to summarise the available evidence examining the 
association between adverse outcomes of pregnancy (HDP, 
GDM, preterm birth, delivery of low birth-weight infant) and 
later maternal renal disease and to synthesise the results 
of relevant studies.
Methods and analysis A systematic search of PubMed, 
EMBASE and Web of Science will be undertaken using 
a detailed prespecified search strategy. Two authors 
will independently review the titles and abstracts of all 
studies, perform data extraction and appraise the quality 
of included studies using a bias classification tool. Original 
case–control and cohort studies published in English 
will be considered for inclusion. Primary outcomes of 
interest will be CKD and ESKD; secondary outcomes will 
be hospitalisation for renal disease and deaths from renal 
disease. Meta-analyses will be performed to calculate 
the overall pooled estimates using the generic inverse 
variance method. The systematic review will follow the 
Meta-analyses Of Observational Studies in Epidemiology 
guidelines.
Ethics and dissemination This systematic review and 
meta-analysis will be based on published data, and thus 
there is no requirement for ethics approval. The results will 
be shared through publication in a peer reviewed journal 
and through presentations at academic conferences.
PrOsPErO registration number CRD42018110891
IntrOduCtIOn
Chronic kidney disease (CKD) is a major 
cause of premature morbidity and mortality 
worldwide, and its prevalence is estimated 
at 11%–13% among women.1 End-stage 
kidney disease (ESKD), although relatively 
rare, causes disproportionately high health-
care burden and expense.2 3 Globally, rising 
levels of obesity, metabolic syndrome and 
advanced maternal age are resulting in 
increasing prevalence of adverse pregnancy 
outcomes, particularly hypertensive disorders 
of pregnancy (HDP) and gestational diabetes 
(GDM).4–6 Pre-eclampsia (PE), gestational 
hypertension and GDM are now recognised 
as independent cardiovascular risk factors 
in women,7 8 while preterm birth, growth 
restriction and gestational weight gain have 
also been linked to future cardiovascular 
disease.9–11 By comparison, relatively little is 
strengths and limitations of this study
 ► This proposed systematic review and meta-analysis 
will provide updated knowledge on the associations 
between common adverse pregnancy outcomes (ie, 
hypertensive disorders of pregnancy, gestational di-
abetes, preterm birth, delivery of low birth-weight 
infants) and the long-term maternal risk of renal 
disease.
 ► The high prevalence of adverse pregnancy out-
comes and chronic kidney disease suggests that 
any potential associations would have important 
public health implications
 ► Screening for eligible studies, data extraction and 
quality assessment will be undertaken by two in-
dependent reviewers to minimise the potential for 
reviewer bias.
 ► A considerable degree of heterogeneity is anticipat-
ed between studies due to differences in diagnos-
tic methods for both exposures and outcomes, and 
varying lengths of follow-up.
 ► Only published studies in the English language will 
be included.
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known about the long-term risk of maternal renal disease 
following complications of pregnancy.
There is some evidence to suggest that PE increases the 
risk of maternal kidney disease later in life. A meta-analysis 
of seven small prospective studies identified an increased 
risk of microalbuminuria among women who experi-
enced PE compared with those who had normal pregnan-
cies after a mean of 7 years follow-up.12 A large Norwegian 
cohort study suggested that pre-eclamptic women were at 
long-term risk of ESKD.13 However, the proposed asso-
ciation may be complicated by the strong links between 
PE and unmeasured cardiovascular risk factors, such as 
maternal obesity, which can independently increase the 
risk of CKD.14
The long-term risk of CKD among these women has 
not been comprehensively addressed by studies to date. 
It is biologically plausible that PE predisposes women 
to higher risk of CKD; PE is associated with abnormal 
placental development, and subsequent development of 
generalised maternal endothelial dysfunction.15 PE may 
thus result in lasting renal endothelial damage, which may 
increase maternal risk of CKD and ESKD.16 PE is just one 
of several HDPs, and it is unknown if women who expe-
rience gestational hypertension, or PE superimposed on 
chronic hypertension, are also at increased long-term risk 
of maternal kidney disease.
A range of other complications of pregnancy may 
increase the risk of future kidney disease in women. Low 
birth-weight and preterm delivery have been reported to 
increase the risk of ESKD in women with PE.13 However, 
it is uncertain whether these associations persist inde-
pendently, or whether birth weight and gestational age 
are mediators of the association with PE. In one Norwe-
gian cohort study, preterm birth was reported to inde-
pendently increase the risk of ESKD, but this study was 
restricted to women with pre-existing diabetes and is not 
generalisable to the wider population.17
GDM is an established risk factor for type 2 diabetes,18 
and may thereby increase the risk of diabetic nephrop-
athy. However, GDM is also an independent risk factor 
for vascular endothelial dysfunction,19 20 and is a plausible 
independent risk factor for maternal kidney disease. To 
date there has been limited research to examine whether 
GDM predicts CKD risk independent of subsequent type 
2 diabetes.
Worldwide, 3%–5% of pregnancies are complicated 
by PE21 , 5%–18% of births are preterm22, 11% have 
low birth-weight23 and 5%–13% are complicated by 
GDM.24 25 Given the high prevalence of CKD,1 any true 
associations between these exposures and CKD may have 
potentially important public health implications, particu-
larly in resource-poor settings where adverse pregnancy 
outcomes are more prevalent. Women with complica-
tions of pregnancy and at risk of CKD, may benefit from 
future risk-reduction interventions or enhanced commu-
nity-based follow-up care to mitigate against possible 
progression to renal disease. Only a minority of indi-
viduals with CKD will ever progress to ESKD, requiring 
dialysis or renal transplant, but they experience prema-
ture mortality,26 27 and place a considerable economic 
and resource burden on health systems.28
The aim of this systematic review and meta-analysis is to 
summarise the available evidence examining the associa-
tion between adverse pregnancy outcomes and long-term 
maternal renal disease. The adverse outcomes of interest 
include HDP (including PE, gestational hypertension, 
chronic hypertension and PE superimposed on chronic 
hypertension), preterm birth, delivery of a low birth-
weight infant and GDM. 
Population
Women who have had at least one pregnancy of at least 
23 weeks gestation.
Exposures
Any one of the following adverse pregnancy outcomes:
1. Diagnosis of HDP (including PE, gestational hyperten-
sion or other HDP).
2. Preterm birth.
3. Diagnosis of GDM.
4. Delivery of a low birth-weight infant (including infants 
who were small for gestational age).
Any of these adverse outcomes can be defined using 
established clinical criteria, hospital records or self-re-
porting of a doctor diagnosis.
Comparison
Women who never had a corresponding adverse outcome 
in pregnancy. For example, women who experienced a 
preterm birth in at least one pregnancy will be compared 
with women who never experienced a preterm birth.
Outcomes
Primary outcome 1: CKD.
Primary outcome 2: ESKD.
These primary outcomes can be defined either using 
established clinical criteria or hospital records.
Secondary outcomes: (1) hospitalisation for renal disease, 
(2) deaths from renal disease.
review question
Does the presence of an adverse pregnancy outcome (ie, 
HDP, preterm birth, delivery of a low birth-weight infant 
or GDM) increase the risk of maternal kidney disease in 
later life?
MEthOds And dEsIgn
This protocol was drafted using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis Proto-
cols checklist.29 The proposed systematic review and 
meta-analysis will follow the Meta-analyses Of Observa-
tional Studies in Epidemiology (MOOSE) guidelines.30
search strategy
The lead author (PMB) will undertake a systematic search 
of the following databases: PubMed, EMBASE and Web 
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of Science. Peer reviewed journal articles published in 
the English language, from inception of databases to 31 
July 2018, will be included. A detailed search strategy has 
been compiled, and the search terms will be combined 
using Boolean Logic where appropriate (AND, OR). The 
detailed search strategy is available in online appendix 1.
The search of the electronic databases will be supple-
mented by hand-searching all included papers to identify 
any further potentially relevant studies.
study selection
The titles and abstracts of studies retrieved from each 
database search will be stored in the EndNote reference 
manager and de-duplicated. Two review authors (PMB, 
SC) will screen all titles and abstracts for potentially rele-
vant studies. The full text of the relevant studies will then 
be retrieved and screened for compliance with eligibility 
criteria by two reviewers (PMB, CJ). If consensus on eligi-
bility cannot be achieved, a third review author will be 
consulted (ASK). For any articles which do not meet 
the inclusion criteria, the reasons for rejection will be 
noted. A MOOSE flow diagram documenting the process 
of study selection will be completed.
Inclusion criteria
 ► Case–control studies and cohort studies (prospective 
or retrospective).
 ► Data provided on an adverse pregnancy outcome 
of interest (ie, diagnosis of HDP, preterm birth, low 
birth-weight or GDM) as an exposure variable.
 ► Data provided on a diagnosis of either CKD or ESKD 
as an outcome variable.
 ► Provides a measure of association between one or 
more of the adverse pregnancy outcomes and CKD 
or ESKD.
 ► The diagnosis of maternal CKD or ESKD is made at 
least 3 months after pregnancy has ended.
 ► Data must be from an original study.
 ► Only English-language studies will be considered, 
including all years from inception of the electronic 
databases until July 2018.
 ► Peer reviewed literature only will be included.
Exclusion criteria
 ► Non-human studies.
 ► Studies that are not in English.
 ► Studies focused on CKD/ESKD risk in the offspring.
 ► Studies focused on risk of maternal acute kidney 
injury, without reference to subsequent CKD/ESKD.
 ► Case reports, case series, letters, commentaries, notes 
and editorials.
 ► Studies focused on women with pre-existing renal 
disease.
data extraction
Data from all eligible studies will be extracted by two 
reviewers (PMB, SC) using a standardised data collection 
form, including the author and year of publication, the 
study design, the exposure(s) and outcome(s) of interest, 
the definition used for each exposure and outcome, 
the stage/severity of the outcome (ie, CKD), length of 
follow-up, the sample size, the confounders adjusted 
for (if any) and the crude and adjusted measures of 
association. Where necessary, corresponding authors of 
published studies will be contacted to obtain any informa-
tion needed relating to effect estimates. Where effect esti-
mates are not available, absolute numbers of events will 
be extracted, and crude measures of association will be 
calculated. If discrepancies arise in data extraction, these 
will be discussed between reviewers, and where necessary, 
a third reviewer will be consulted to achieve consensus 
(ASK).
Quality appraisal of included studies
The quality of all included studies will be independently 
assessed by two reviewers  (PMB, CJ) using an established 
quality assessment tool for observational studies. This 
tool has been described in detail elsewhere.31 Six types 
of biases will be assessed: selection, exposure, outcome, 
analytical, attrition and confounding. For each study, 
each component will be assigned a risk of bias cate-
gory: minimal, low, moderate, high or not reported. For 
example, selection bias will be categorised as ‘minimal’ 
if the sample was from a ‘consecutive unselected popula-
tion’, whereas selection bias will be categorised as ‘high’ if 
sample selection is unclear and if the sample is not repre-
sentative of the population of interest. For each included 
study, the overall likelihood of bias will be assessed and 
reported. Where discrepancies in quality appraisal arise, 
a third reviewer will be consulted to achieve consensus 
(ASK).
data synthesis and assessment for heterogeneity
Separate meta-analyses will be undertaken for each of 
the exposure variables and two primary outcomes where 
possible. Each meta-analysis will be undertaken to calcu-
late the pooled estimate of the relationship between the 
adverse outcome of interest and subsequent development 
of maternal CKD or ESKD. For example, for preterm 
birth as the adverse outcome of interest, a meta-analysis 
will be undertaken to investigate the association between 
(1) preterm birth and CKD and (2) preterm birth and 
ESKD. For HDP, a meta-analysis will be undertaken to 
investigate the association between (1) any HDP and CKD 
and (2) any HDP and ESKD. Where possible, subgroup 
analyses will investigate the associations between PE, 
gestational hypertension and any other HDP with each of 
the primary outcomes respectively. For delivery of infants 
with low birth- weight, a meta-analysis will be undertaken 
to investigate the association between (1) low birth-weight 
infant and maternal CKD and (2) low birth-weight infant 
and maternal ESKD. Where possible, subgroup analyses 
will investigate the associations between infants small for 
their gestational age with each of the primary outcomes, 
respectively.
Both crude and adjusted effect estimates will be displayed 
using the generic inverse variance method. Adjustment 
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will be based on the definition outlined in each of the 
individual studies. Heterogeneity will be explored based 
on I2 values and χ2 statistics. Random-effects models will 
be used if moderate or high levels of heterogeneity are 
observed between the studies of interest. If studies cannot 
be meaningfully combined in a meta-analysis, they will be 
presented in tabular format.
We will perform the following subgroup/sensitivity anal-
yses, where the data allow, using RevMan V.5.3: (1) study 
type (case–control vs cohort study), (2) stage/severity 
of CKD, (3) ethnic group, (4) length of follow-up after 
index pregnancy, (5) number of pregnancies affected by 
the adverse outcome, (6) measurement of exposure and 
outcome data (self-reported vs medical records vs labora-
tory measurements), (7) study quality (minimal/low risk 
of bias vs moderate/high risk of bias). Furthermore, any 
studies which have not excluded women with pre-existing 
renal disease, or have not adjusted for this factor, will be 
considered in a separate subgroup analysis.
Where 10 or more studies are included in a meta-anal-
ysis, we will assess the publication bias. The trim and fill 
method will be used to identify and correct for funnel plot 
asymmetry arising from publication bias, if appropriate.32
Ethics and dissemination
This protocol is based on published data, and thus there 
is no requirement for ethics approval. The results will 
be disseminated through publication in a peer reviewed 
journal, and through presentations at academic 
conferences.
Patient and public involvement
Patients were not involved in the design of this system-
atic review and meta-analysis. However, the authors will 
communicate the study findings to patient and public 
groups with interest in this area, including action on 
preeclampsia.
Potential limitations
There are a number of limitations anticipated in this 
review. Publication bias may reduce the likelihood of 
retrieving studies which report non-significant associa-
tions between adverse pregnancy outcomes and maternal 
renal disease. Due to limited resources, only studies which 
are published in the English language will be included. 
Publications which only use biomarkers of renal function 
as outcome variables (eg, microalbuminuria, albumin/
creatinine ratio, estimated glomerular filtration rate) will 
not be included unless they are directly related to a diag-
nosis of CKD or ESKD.
A degree of heterogeneity is anticipated between 
studies. Differences in diagnostic methods are likely 
for both exposures and outcomes. The timeframe for 
follow-up is likely to vary considerably between studies, 
with women followed up for longer durations more likely 
to have developed renal disease. The ability to identify 
true associations between adverse pregnancy outcomes 
and future CKD or ESKD will be limited by the length of 
follow-up in each of the included studies. Differences in 
sampling frames are also likely to lead to heterogeneity. 
Thus, a random-effects model will be used for meta-anal-
yses with moderate or high heterogeneity.
The presence of selection bias and residual confounding 
is a concern in all observational studies. Potential 
confounders may include maternal age, ethnic group, 
socio-economic status, parity, family history, hyperten-
sion, diabetes, cardiovascular disease, systemic inflamma-
tory disease, hyperlipidaemia, obesity and smoking. Our 
meta-analyses will display both crude and adjusted results 
where possible, basing adjustment on the definition 
outlined in each individual study. However, given that 
less adjusted effect estimates may skew the overall results, 
a sensitivity analysis will be undertaken, where possible, 
to examine effect estimates which are adjusted more 
fully for confounders (ie, adjusted for, at a minimum, 
maternal age, hypertension, diabetes, obesity, smoking, 
pre-existing kidney disease).
dIsCussIOn
There is a lack of consensus on whether adverse preg-
nancy outcomes, such as HDP, preterm birth, delivery 
of a low birth-weight infant and GDM, independently 
increase the risk of maternal CKD and ESKD. This system-
atic review and meta-analysis will summarise the available 
evidence which has examined these associations, thus 
providing novel information on the role of pregnancy-re-
lated factors in the aetiology of maternal renal disease.
Contributors PMB, FPMcC, IJP and ASK conceived and designed the protocol, and 
PMB drafted the protocol manuscript. PMB developed the search strategy, with 
input from FPMcC, IJP and ASK. PMB, CJ and ASK planned the data extraction. PMB, 
SC and AK planned the quality appraisal of all included studies. PMB, FPMcC, IJP, 
SC, CJ, KK, MK, ME, PS and ASK critically revised the manuscript for methodological 
and intellectual content. All authors approved the final version.
Funding This work was performed within the Irish Clinical Academic Training 
programme, supported by the Wellcome Trust and the Health Research Board (Grant 
number 203930/B/16/Z), the Health Service Executive National Doctors Training 
and Planning and the Health and Social Care, Research and Development division, 
Northern Ireland. 
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of Chronic 
Kidney Disease - a systematic review and meta-analysis. PLoS One 
2016;11:e0158765.
 2. Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic 
kidney disease to the global burden of major noncommunicable 
diseases. Kidney Int 2011;80:1258–70.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027180 on 5 May 2019. Downloaded from 
5Barrett PM, et al. BMJ Open 2019;9:e027180. doi:10.1136/bmjopen-2018-027180
Open access
 3. Eggers PW. Has the incidence of end-stage renal disease in the 
USA and other countries stabilized? Curr Opin Nephrol Hypertens 
2011;20:241–5.
 4. Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders 
of pregnancy: a systematic review of international clinical practice 
guidelines. PLoS One 2014;9:e113715.
 5. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr 
Rev 2013;71(Suppl 1):S18–25.
 6. Di Cianni G, Miccoli R, Volpe L, et al. Intermediate metabolism in 
normal pregnancy and in gestational diabetes. Diabetes Metab Res 
Rev 2003;19:259–70.
 7. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines 
for the prevention of cardiovascular disease in women--2011 update: 
a guideline from the American Heart Association. J Am Coll Cardiol 
2011;57:1404–23.
 8. Bushnell C, McCullough L. Stroke prevention in women: synopsis of 
the 2014 American Heart Association/American Stroke Association 
guideline. Ann Intern Med 2014;160:853–7.
 9. van Kesteren F, Visser S, Hermes W, et al. Counselling and 
management of cardiovascular risk factors after preeclampsia. 
Hypertens Pregnancy 2016;35:55–61.
 10. Cirillo PM, Cohn BA. Pregnancy complications and 
cardiovascular disease death: 50-year follow-up of the Child 
Health and Development Studies pregnancy cohort. Circulation 
2015;132:1234–42.
 11. Heida KY, Velthuis BK, Oudijk MA, et al. Cardiovascular disease 
risk in women with a history of spontaneous preterm delivery: 
A systematic review and meta-analysis. Eur J Prev Cardiol 
2016;23:253–63.
 12. McDonald S, Han Z, Michael W, et al. W15.5 Renal disease after 
preeclampsia: a systematic review and meta-analyses. Pregnancy 
Hypertens 2010;1:S41.
 13. Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of 
end-stage renal disease. N Engl J Med 2008;359:800–9.
 14. Lastra G, Manrique C, Sowers JR. Obesity, cardiometabolic 
syndrome, and chronic kidney disease: the weight of the evidence. 
Adv Chronic Kidney Dis 2006;13:365–73.
 15. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with 
failure of human cytotrophoblasts to mimic a vascular adhesion 
phenotype. One cause of defective endovascular invasion in this 
syndrome? J Clin Invest 1997;99:2152–64.
 16. Rangaswami J, Naranjo M, McCullough PA. Preeclampsia as 
a Form of Type 5 Cardiorenal Syndrome: An Underrecognized 
Entity in Women's Cardiovascular Health. Cardiorenal Med 
2018;8:160–72.
 17. Sandvik MK, Iversen BM, Irgens LM, et al. Are adverse pregnancy 
outcomes risk factors for development of end-stage renal disease in 
women with diabetes? Nephrol Dial Transplant 2010;25:3600–7.
 18. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus 
after gestational diabetes: a systematic review and meta-analysis. 
Lancet 2009;373:1773–9.
 19. Knock GA, McCarthy AL, Lowy C, et al. Association of gestational 
diabetes with abnormal maternal vascular endothelial function. Br J 
Obstet Gynaecol 1997;104:229–34.
 20. Lappas M. Markers of endothelial cell dysfunction are increased 
in human omental adipose tissue from women with pre-
existing maternal obesity and gestational diabetes. Metabolism 
2014;63:860–73.
 21. American College of Obstetricians and GynecologistsTask Force on 
Hypertension in Pregnancy. Hypertension in pregnancy. Report of the 
American College of Obstetricians and Gynecologists’ Task Force on 
Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122–31.
 22. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, 
and worldwide estimates of preterm birth rates in the year 2010 with 
time trends since 1990 for selected countries: a systematic analysis 
and implications. Lancet 2012;379:2162–72.
 23. The World Bank. Low-birthweight babies (% of births). 2018 https:// 
data. worldbank. org/ indicator/ SH. STA. BRTW. ZS.
 24. Eades CE, Cameron DM, Evans JMM. Prevalence of gestational 
diabetes mellitus in Europe: a meta-analysis. Diabetes Res Clin Pract 
2017;129:173–81.
 25. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of 
progression to Type 2 Diabetes: a Global Perspective. Curr Diab Rep 
2016;16:7.
 26. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease 
and mortality risk: a systematic review. J Am Soc Nephrol 
2006;17:2034–47.
 27. Di Angelantonio E, Chowdhury R, Sarwar N, et al. Chronic kidney 
disease and risk of major cardiovascular disease and non-vascular 
mortality: prospective population based cohort study. BMJ 
2010;341:c4986.
 28. Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and 
beyond: a roadmap for closing gaps in care, research, and policy. 
Lancet 2017;390:1888–917.
 29. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015 
statement. Syst Rev 2015;4:1.
 30. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of 
observational studies in epidemiology: a proposal for reporting. 
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
group. JAMA 2000;283:2008–12.
 31. McDonald SD, Han Z, Mulla S, et al. Preterm birth and low birth 
weight among in vitro fertilization singletons: a systematic review and 
meta-analyses. Eur J Obstet Gynecol Reprod Biol 2009;146:138–48.
 32. Weinhandl ED, Duval S. Generalization of trim and fill for application 
in meta-regression. Res Synth Methods 2012;3:51–67.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027180 on 5 May 2019. Downloaded from 
